These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38043528)

  • 1. Expression of Nectin-4 in Chromophobe Renal Cell Carcinoma in a Multicenter Cohort: Early Prognostic and Therapeutic Considerations.
    Mikuteit M; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F
    Oncology; 2024; 102(6):503-509. PubMed ID: 38043528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of claudin-6 in chromophobe renal cell carcinoma.
    Erlmeier F; Zschäbitz S; Mikuteit M; Autenrieth M; Weichert W; Hartmann A; Steffens S
    Histol Histopathol; 2023 Apr; 38(4):403-407. PubMed ID: 36128931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trophoblast Cell Surface Antigen 2 (Trop2) in Chromophobe Renal Cell Carcinoma.
    Mikuteit M; Steffens S; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Erlmeier F
    Oncology; 2022; 100(6):331-336. PubMed ID: 35168242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma.
    Mikuteit M; Zschäbitz S; Erlmeier M; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F
    Oncology; 2022; 100(10):536-541. PubMed ID: 35760058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?
    Erlmeier F; Hartmann A; Autenrieth M; Wiedemann M; Ivanyi P; Steffens S; Weichert W
    Med Oncol; 2016 Nov; 33(11):120. PubMed ID: 27696122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma.
    Erlmeier M; Mikuteit M; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F
    BMC Urol; 2023 May; 23(1):90. PubMed ID: 37170275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L2: A prognostic marker in chromophobe renal cell carcinoma?
    Erlmeier F; Weichert W; Autenrieth M; Wiedemann M; Schrader AJ; Hartmann A; Ivanyi P; Steffens S
    Med Oncol; 2017 May; 34(5):71. PubMed ID: 28353093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.
    Steffens S; Roos FC; Janssen M; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Junker K; Kuczyk MA; Schrader AJ;
    Virchows Arch; 2014 Oct; 465(4):439-44. PubMed ID: 25178561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DOG1, cyclin D1, CK7, CD117 and vimentin are useful immunohistochemical markers in distinguishing chromophobe renal cell carcinoma from clear cell renal cell carcinoma and renal oncocytoma.
    Zhao W; Tian B; Wu C; Peng Y; Wang H; Gu WL; Gao FH
    Pathol Res Pract; 2015 Apr; 211(4):303-7. PubMed ID: 25596994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of nectin-4 in papillary renal cell carcinoma.
    Zschäbitz S; Mikuteit M; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Duensing S; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Erlmeier F; Steffens S
    Discov Oncol; 2022 Sep; 13(1):90. PubMed ID: 36136143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leptin and its receptor: can they help to differentiate chromophobe renal cell carcinoma from renal oncocytoma?
    Ng KL; Del Vecchio SJ; Samaratunga H; Morais C; Rajandram R; Vesey DA; Wood ST; Gobe GC
    Pathology; 2018 Aug; 50(5):504-510. PubMed ID: 29970253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Met in chromophobe renal cell carcinoma.
    Erlmeier F; Ivanyi P; Hartmann A; Autenrieth M; Wiedemann M; Weichert W; Steffens S
    Med Oncol; 2017 Feb; 34(2):15. PubMed ID: 28035577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series.
    Casuscelli J; Becerra MF; Seier K; Manley BJ; Benfante N; Redzematovic A; Stief CG; Hsieh JJ; Tickoo SK; Reuter VE; Coleman JA; Russo P; Ostrovnaya I; Hakimi AA
    Clin Genitourin Cancer; 2019 Oct; 17(5):373-379.e4. PubMed ID: 31326335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical study of c-KIT (CD117) expression in renal cell carcinoma.
    Ahmed EA; Youssif ME
    J Egypt Natl Canc Inst; 2009 Jun; 21(2):121-32. PubMed ID: 21057563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
    Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
    Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis.
    Avulova S; Cheville JC; Lohse CM; Gupta S; Potretzke TA; Tsivian M; Thompson RH; Boorjian SA; Leibovich BC; Potretzke AM
    Eur Urol; 2021 Feb; 79(2):225-231. PubMed ID: 33172723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.
    Tschirdewahn S; Panic A; Püllen L; Harke NN; Hadaschik B; Riesz P; Horváth A; Szalontai J; Nyirády P; Baba HA; Reis H; Szarvas T
    Int J Cancer; 2019 Jul; 145(2):531-539. PubMed ID: 30650187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
    Klümper N; Ralser DJ; Ellinger J; Roghmann F; Albrecht J; Below E; Alajati A; Sikic D; Breyer J; Bolenz C; Zengerling F; Erben P; Schwamborn K; Wirtz RM; Horn T; Nagy D; Toma M; Kristiansen G; Büttner T; Hahn O; Grünwald V; Darr C; Erne E; Rausch S; Bedke J; Schlack K; Abbas M; Zschäbitz S; Schwab C; Mustea A; Adam P; Manseck A; Wullich B; Ritter M; Hartmann A; Gschwend J; Weichert W; Erlmeier F; Hölzel M; Eckstein M
    Clin Cancer Res; 2023 Apr; 29(8):1496-1505. PubMed ID: 36534531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.